Skip to main content
. 2024 Aug 2;30(8):2295–2302. doi: 10.1038/s41591-024-03169-2

Table 3.

Changes in plasma NT-proBNP levels from baseline to follow-up at 3 months

Parameter QLQX (n = 1,109) P (intragroup) Placebo (n = 1,109) P (intragroup) P (intergroup)
Difference in NT-proBNPa (median (IQR); pg ml−1) −444.00 (−1401.00, 85.00) <0.001 −363.00 (−1,280.00, 183.00) <0.001 0.047
Percent reduction in NT-proBNPb (median (IQR); %) 38.84 (−6.83, 69.94) 29.67 (−16.42, 66.48) 0.001
Patients with reduction in NT-proBNP of >30% (n (%)) 627 (56.54%) 553 (49.86%) 0.002

Intergroup significance was tested using Student's t-test for continuous variables and the chi-square or Wilcoxon test for categorical variables, with the Wilcoxon paired signed-rank test used for intragroup comparisons. P values are two-sided.

aDifference in NT-proBNP = baseline level − 3-month level.

bPercent reduction in NT-proBNP = (baseline level − 3-month level)/baseline level × 100.